891 research outputs found
Hypertriglyceridaemiaâinduced pancreatitis prompted by acute corticosteroid treatment: caution for clinicians
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/148397/1/imj14228.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/148397/2/imj14228_am.pd
Impact of diatom-diazotroph associations on carbon export in the Amazon River plume
Offshore tropical river plumes are associated with areas of high N-2 fixation (diazotrophy) and biological carbon drawdown. Episodic blooms of the diatom Hemiaulus hauckii and its diazotrophic cyanobacterial symbiont Richelia intracellularis are believed to dominate that carbon drawdown, but the mechanism is not well understood. We report primary productivity associated with blooms of these diatom-diazotroph assemblages (DDAs) in the offshore plume of the Amazon River using simultaneous measurements of O-2/Ar ratios and the triple-isotope composition of dissolved O-2. In these blooms, we observe peaks in net community productivity, but relatively small changes in gross primary productivity, suggesting that DDA blooms increase the ecosystem carbon export ratio more than twofold. These events of enhanced export efficiency lead to biological uptake of dissolved inorganic carbon and silicate, whose longer mixed-layer residence times otherwise obscure the differential impact of DDAs. The shorter-term rate estimates presented here are consistent with the results derived from longer-term geochemical tracers, confirming that DDAs drive a significant biological CO2 pump in tropical oceans
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Background The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. Methods In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The primary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcome, with a margin of 1.30 for the upper boundary of the 95% confidence interval of the hazard ratio. No adjustments for multiplicity were performed for the prespecified exploratory outcomes. Results A total of 9340 patients underwent randomization. The median follow-up was 3.8 years. The primary outcome occurred in significantly fewer patients in the liraglutide group (608 of 4668 patients [13.0%]) than in the placebo group (694 of 4672 [14.9%]) (hazard ratio, 0.87; 95% confidence interval [CI], 0.78 to 0.97; P<0.001 for noninferiority; P=0.01 for superiority). Fewer patients died from cardiovascular causes in the liraglutide group (219 patients [4.7%]) than in the placebo group (278 [6.0%]) (hazard ratio, 0.78; 95% CI, 0.66 to 0.93; P=0.007). The rate of death from any cause was lower in the liraglutide group (381 patients [8.2%]) than in the placebo group (447 [9.6%]) (hazard ratio, 0.85; 95% CI, 0.74 to 0.97; P=0.02). The rates of nonfatal myocardial infarction, nonfatal stroke, and hospitalization for heart failure were nonsignificantly lower in the liraglutide group than in the placebo group. The most common adverse events leading to the discontinuation of liraglutide were gastrointestinal events. The incidence of pancreatitis was nonsignificantly lower in the liraglutide group than in the placebo group. Conclusions In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo. (Funded by Novo Nordisk and the National Institutes of Health; LEADER ClinicalTrials.gov number, NCT01179048 .)
Poisson-de Rham homology of hypertoric varieties and nilpotent cones
We prove a conjecture of Etingof and the second author for hypertoric
varieties, that the Poisson-de Rham homology of a unimodular hypertoric cone is
isomorphic to the de Rham cohomology of its hypertoric resolution. More
generally, we prove that this conjecture holds for an arbitrary conical variety
admitting a symplectic resolution if and only if it holds in degree zero for
all normal slices to symplectic leaves.
The Poisson-de Rham homology of a Poisson cone inherits a second grading. In
the hypertoric case, we compute the resulting 2-variable Poisson-de
Rham-Poincare polynomial, and prove that it is equal to a specialization of an
enrichment of the Tutte polynomial of a matroid that was introduced by Denham.
We also compute this polynomial for S3-varieties of type A in terms of Kostka
polynomials, modulo a previous conjecture of the first author, and we give a
conjectural answer for nilpotent cones in arbitrary type, which we prove in
rank less than or equal to 2.Comment: 25 page
Observations of the lunar plasma wake from the WIND spacecraft on December 27, 1994
On December 27, 1994, the WIND spacecraft crossed the lunar wake at a distance of 6.5 lunar radii ( RL ) behind the moon. The observations made were the first employing modem instruments and a high data rate. The SWE plasma instrument on WIND observed new aspects of the interaction between the solar wind and unmagnetized dielectric bodies. The plasma density decreased exponentially from the periphery of the wake towards its center as predicted by simple theory. Behind the moon two distinct cold ion beams were observed refilling the lunar cavity. The ions were accelerated along the direction of the magnetic field by an electric field of the order 2 Ă 10â4 volts/m. The region of plasma depletion was observed to extend beyond the light shadow, consistent with a rarefaction wave moving out from the wake into the undisturbed solar wind
2015 ACVIM Small Animal Consensus Statement on Seizure Management in Dogs
This report represents a scientific and working clinical consensus statement on seizure management in dogs based on current literature and clinical expertise. The goal was to establish guidelines for a predetermined, concise, and logical sequential approach to chronic seizure management starting with seizure identification and diagnosis (not included in this report), reviewing decisionâmaking, treatment strategies, focusing on issues related to chronic antiepileptic drug treatment response and monitoring, and guidelines to enhance patient response and quality of life. Ultimately, we hope to provide a foundation for ongoing and future clinical epilepsy research in veterinary medicine
Development and preliminary evaluation of the VPS ReplaySuite: a virtual double-headed microscope for pathology
BACKGROUND: Advances in computing and telecommunications have resulted in the availability of a range of online tools for use in pathology training and quality assurance. The majority focus on either enabling pathologists to examine and diagnose cases, or providing image archives that serve as reference material. Limited emphasis has been placed on analysing the diagnostic process used by pathologists to reach a diagnosis and using this as a resource for improving diagnostic performance. METHODS: The ReplaySuite is an online pathology software tool that presents archived virtual slide examinations to pathologists in an accessible video-like format, similar to observing examinations with a double-headed microscope. Delivered through a customised web browser, it utilises PHP (Hypertext PreProcessor) to interact with a remote database and retrieve data describing virtual slide examinations, performed using the Virtual Pathology Slide (VPS). To demonstrate the technology and conduct a preliminary evaluation of pathologists opinions on its potential application in pathology training and quality assurance, 70 pathologists were invited to use the application to review their own and other pathologists examinations of 10 needle-core breast biopsies and complete an electronic survey. 9 pathologists participated, and all subsequently completed an exit survey. RESULTS: Of those who replayed an examination by another pathologist, 83.3% (5/6) agreed that replays provided an insight into the examining pathologists diagnosis and 33.3% (2/6) reconsidered their own diagnosis for at least one case. Of those who reconsidered their original diagnosis, all re-classified either concordant with group consensus or original glass slide diagnosis. 77.7% (7/9) of all participants, and all 3 participants who replayed more than 10 examinations stated the ReplaySuite to be of some or great benefit in pathology training and quality assurance. CONCLUSION: Participants conclude the ReplaySuite to be of some or of great potential benefit to pathology training and quality assurance and consider the ReplaySuite to be beneficial in evaluating the diagnostic trace of an examination. The ReplaySuite removes temporal and spatial issues that surround the use of double-headed microscopes by allowing examinations to be reviewed at different times and in different locations to the original examination. While the evaluation set was limited and potentially subject to bias, the response of participants was favourable. Further work is planned to determine whether use of the ReplaySuite can result in improved diagnostic ability
Simvastatin decreases the level of heparin-binding protein in patients with acute lung injury
Background: Heparin-binding protein is released by neutrophils during inflammation and disrupts the integrity of the alveolar and capillary endothelial barrier implicated in the development of acute lung injury and systemic organ failure. We sought to investigate whether oral administration of simvastatin to patients with acute lung injury reduces plasma heparin-binding protein levels and improves intensive care unit outcome. Methods: Blood samples were collected from patients with acute lung injury with 48 h of onset of acute lung injury (day 0), day 3, and day 7. Patients were given placebo or 80 mg simvastatin for up to 14 days. Plasma heparin-binding protein levels from patients with acute lung injury and healthy volunteers were measured by ELISA. Results: Levels of plasma heparin-binding protein were significantly higher in patients with acute lung injury than healthy volunteers on day 0 (p = 0.011). Simvastatin 80 mg administered enterally for 14 days reduced plasma level of heparin-binding protein in patients. Reduced heparin-binding protein was associated with improved intensive care unit survival. Conclusions: A reduction in heparin-binding protein with simvastatin is a potential mechanism by which the statin may modify outcome from acute lung injury
Meta-analysis of prophylactic corticosteroid use in post-ERCP pancreatitis
<p>Abstract</p> <p>Background</p> <p>Acute pancreatitis is a common complication of endoscopic retrograde cholangiopancreatography and benefit of pharmacological treatment is unclear. Although prophylactic use of corticosteroid for reduction of pancreatic injury after ERCP has been evaluated, discrepancy about beneficial effect of corticosteroid on pancreatic injury still exists. The aim of current study is to evaluate effectiveness and safety of corticosteroid in prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP).</p> <p>Methods</p> <p>We employed the method recommended by the Cochrane Collaboration to perform a meta-analysis of seven randomized controlled trials (RCTs) of corticosteroid in prevention of post-ERCP pancreatitis (PEP) around the world.</p> <p>Results</p> <p>Most of the seven RCTs were of high quality. When the RCTs were analyzed, odds ratios (OR) for corticosteroid were 1.13 [95% CI (0.89~1.44), p = 0.32] for PEP, 1.61 [95% CI (0.74~3.52), p = 0.23] for severe PEP, 0.92 [95% CI (0.57~1.48), p = 0.73] for post-ERCP hyperamylasemia respectively. The results indicated that there were no beneficial effects of corticosteroid on acute pancreatitis and hyperamylasemia. No evidence of publication bias was found.</p> <p>Conclusion</p> <p>Corticosteroids cannot prevent pancreatic injury after ERCP. Therefore, their use in the prophylaxis of PEP is not recommended.</p
International Veterinary Epilepsy Task Force consensus proposal: Medical treatment of canine epilepsy in Europe
In Europe, the number of antiepileptic drugs (AEDs) licensed for dogs has grown considerably over the last years. Nevertheless, the same questions remain, which include, 1) when to start treatment, 2) which drug is best used initially, 3) which adjunctive AED can be advised if treatment with the initial drug is unsatisfactory, and 4) when treatment changes should be considered. In this consensus proposal, an overview is given on the aim of AED treatment, when to start long-term treatment in canine epilepsy and which veterinary AEDs are currently in use for dogs. The consensus proposal for drug treatment protocols, 1) is based on current published evidence-based literature, 2) considers the current legal framework of the cascade regulation for the prescription of veterinary drugs in Europe, and 3) reflects the authorsâ experience. With this paper it is aimed to provide a consensus for the management of canine idiopathic epilepsy. Furthermore, for the management of structural epilepsy AEDs are inevitable in addition to treating the underlying cause, if possible
- âŠ